Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema
Thomas A. Ciulla, MD, MBA, FASRS
Updates from the Field
2017
Hyalocyte Apoptosis in Vitreous Microparticles Suggest a Diabetic Vitreopathy
Harris C Sultan, MS, MD
On Demand Cases, Courses, and Papers
2019

Category: Diabetic Retinopathy

See more